Tim MBA - HLS Therapeutics Chief Officer
| HLS Stock | CAD 4.49 0.01 0.22% |
Insider
Tim MBA is Chief Officer of HLS Therapeutics
| Age | 52 |
| Address | 10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2 |
| Phone | 647 495 9000 |
| Web | https://www.hlstherapeutics.com |
HLS Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0186) % which means that it has lost $0.0186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2002) %, meaning that it generated substantial loss on money invested by shareholders. HLS Therapeutics' management efficiency ratios could be used to measure how well HLS Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of February 2026, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.06. At this time, HLS Therapeutics' Intangible Assets are very stable compared to the past year. As of the 4th of February 2026, Debt To Assets is likely to grow to 0.55, while Total Assets are likely to drop about 116.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Schmitt | Auxly Cannabis Group | N/A | |
| Hugo Alves | Auxly Cannabis Group | 54 | |
| MBA MBA | Helix BioPharma Corp | 63 | |
| Ian Rapsey | Auxly Cannabis Group | 47 | |
| Trevor Burns | Cardiol Therapeutics Class | N/A | |
| Zohar Krivorot | Cannara Biotech | 49 | |
| Avi Krivorot | Cannara Biotech | N/A | |
| MBA MBA | Cardiol Therapeutics Class | N/A | |
| Kevin Furet | Auxly Cannabis Group | N/A | |
| Michael Lickver | Auxly Cannabis Group | 41 | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Bernard BSc | Cardiol Therapeutics Class | N/A | |
| Dr MA | Helix BioPharma Corp | N/A | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Alexander Wolfe | Cannara Biotech | N/A | |
| CA CMA | Cardiol Therapeutics Class | N/A | |
| Alan Cooke | Auxly Cannabis Group | N/A | |
| Ren Goehrum | Biosyent | 67 | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0186 |
HLS Therapeutics Leadership Team
Elected by the shareholders, the HLS Therapeutics' board of directors comprises two types of representatives: HLS Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLS. The board's role is to monitor HLS Therapeutics' management team and ensure that shareholders' interests are well served. HLS Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLS Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA LLB, CoFounder Chairman | ||
| Brian Walsh, Senior Commercial | ||
| Sanjiv Sharma, Chief Officer | ||
| JD BA, HR Legal | ||
| David Spence, Co Controller | ||
| CPA CGA, Interim Director | ||
| Jason PharmD, Vice Affairs | ||
| Gilbert Godin, CEO CoFounder | ||
| Tim MBA, Chief Officer | ||
| Dave Mason, Investor Officer | ||
| John Hanna, Interim Director | ||
| Craig MBA, CEO Director |
HLS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HLS Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0186 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 199.8 M | ||||
| Shares Outstanding | 31.27 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 43.32 % | ||||
| Number Of Shares Shorted | 2.12 K | ||||
| Price To Book | 1.66 X |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.